Background. Optimal empiric therapy for hospitalized patients with healthcare-associated pneumonia (HCAP) is uncertain.
The 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines for nosocomial pneumonia defined healthcare-associated pneumonia (HCAP) as including patients who had recent contact with healthcare environments through nursing homes, hemodialysis centers, or recent hospitalization, recommending that all patients with HCAP be treated empirically with multiple antibiotics, directed against multidrugresistant (MDR) pathogens [1] . Recently, however, there has been opposition to this approach, because not all HCAP patients are at risk for MDR pathogen infection [2, 3] .
Several recent studies have shown that HCAP patients are a heterogeneous group. Some studies, mainly from the United States, reported a higher frequency of drug-resistant pathogens and mortality in HCAP than in CAP [4, 5] , whereas several European studies found a lower frequency of drug-resistant pathogens and demonstrated the efficacy of narrow-spectrum therapy [6] [7] [8] . Nursing home-acquired pneumonia (one type of HCAP) in Japan and Spain has a mortality rate and etiology more similar to CAP than to hospital-acquired pneumonia (HAP) [9] [10] [11] . It is desirable not to use aggressive empiric combination therapy for HCAP patients if it is not necessary, as it may possibly lead to drug toxicity, as well as promoting future antimicrobial resistance [12] .
In 2009 Brito and Niederman proposed a therapeutic strategy that divided HCAP patients into 4 groups based on severity of illness (ie, the need for mechanical ventilation or intensive care unit [ICU] admission) and the presence of other risk factors for MDR pathogens [2] . CAP therapy was recommended for HCAP patients with 0-1 MDR risk factor, and HAP therapy with a 2-or 3-drug regimen was recommended for HCAP patients with ≥2 MDR risk factors.
In reviewing previous reports of HCAP in Japan [10, 13] , we found that not every patient with HCAP had MDR pathogens or required treatment for them. Furthermore, there was no Japanese guideline for HCAP at the time of this investigation. Therefore, we conducted a prospective multicenter cohort study to evaluate the efficacy of the above algorithm for guiding the initial empiric therapy for HCAP.
METHODS
This prospective multicenter cohort study was conducted between June 2009 and May 2011 at 6 Japanese hospitals. Informed consent was obtained from eligible patients. The study was approved by the Committee for Ethics and Clinical Investigation of each participating hospital, and was registered with the Japan Medical Association Center for Clinical Trials ( JMA-IIA00054).
Definitions of CAP and HCAP and Algorithm for Therapy
All patients were hospitalized and had radiographically confirmed pneumonia and appropriate clinical findings (Supplementary Data). Patients with hospital-acquired pneumonia (HAP), pulmonary tuberculosis, and an infiltrate other than pneumonia were excluded. HCAP and CAP were defined according to the ATS/IDSA guidelines [1] . HCAP inclusion criteria are listed in the Supplementary Data. HCAP patients were classified into 4 groups on the basis of severity of the illness and the presence of other risk factors for MDR pathogens (Figure 1 ). Severe illness included needing mechanical ventilation or ICU admission. Other risk factors for MDR pathogens were (1) immune suppression (Supplementary Data), (2) hospitalization within the last 90 days, (3) poor functional status (Barthel Index score <50), and (4) antibiotic therapy within the past 6 months.
HCAP patients with 0-1 MDR risk factor (groups 1 and 3) were treated with CAP therapy (a β-lactam in combination with a macrolide, or a quinolone), whereas HCAP patients with ≥2 MDR risk factors (groups 2 and 4) were treated with HAP therapy (2-or 3-drug regimen that included an antipseudomonal β-lactam in combination with a quinolone or aminoglycoside, plus either optional linezolid or vancomycin) (Figure 2 ).
Outcome Measures and Clinical Assessment
We compared the baseline characteristics, presence of MDR risk factors, etiology, antibiotic regimens, and outcomes for (1) CAP vs HCAP patients, (2) HCAP patients with 0-1 MDR risk factor vs patients with ≥2 MDR risk factors, and (3) nonsevere HCAP vs severe HCAP patients.
The CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥65) and Pneumonia Severity Index (PSI) scores were used to assess the severity of pneumonia [14, 15] . The activities of daily living (ADL) were evaluated using the Barthel Index, which was scored from 0 to 100 based on 10 variables (Supplementary Data) [16] . Patients with <50 points were defined as having poor functional status.
Inappropriate therapy was defined when a defined etiologic pathogen was resistant to the initial antibiotic regimen. Measured outcomes were 30-day mortality and initial treatment failure, defined as a change from the initial therapeutic agents after 48 hours, due to detection of pathogens resistant to initial therapy or clinical instability (Supplementary Data). Patients were followed from the time of onset of pneumonia for 30 days or until the day of death.
Microbiologic Evaluation
Sputum, nasopharyngeal swabs (for polymerase chain reaction [PCR] and culture), serum, urine, and 2 samples of blood were collected for microbiologic examination, and microimmunofluorescence was used to measure for immunoglobulin G and immunoglobulin M antibodies against Chlamydophila (Supplementary Data) [17] [18] [19] [20] . The antimicrobial susceptibility of isolated bacterial pathogens was assessed on the basis of the minimum inhibitory concentration [21] . Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Acinetobacter baumannii, and extended-spectrum β-lactamase (ESBL)-producing organisms were defined as MDR pathogens based on the ATS/IDSA guidelines [1] .
Etiologic Diagnosis
The etiologic diagnosis was considered definitive when any of the prespecified criteria were met (Supplementary Data). A presumptive diagnosis of a pathogen was made if there was heavy growth (≥10 7 colony-forming units/mL) in culture of a predominant bacterium from sputum and Gram staining was considered consistent with that pathogen.
Statistical Analysis
Data were expressed as the mean ± standard deviation and analyzed using the SPSS software package (version 19.0; SPSS Inc, an IBM company). Univariate analysis was carried out using the χ 2 test or Fisher exact test for categorical data and the Mann-Whitney U test for continuous variables. Univariate and multivariate logistic regression analyses were performed to predict 30-day mortality (dependent variable). The independent variables are listed in the Supplementary Data. Variables that showed a significant difference (P < .1) in the univariate analysis were included in the forward likelihood ratio stepwise multivariate logistic regression model to determine if any of them were independently related to outcome. The HosmerLemeshow goodness-of-fit test was performed to assess the overall fit of the model. All reported P values are 2-tailed, with a P value <.05 considered statistically significant.
RESULTS

Patient Characteristics
Four hundred sixty-nine patients with suspected pneumonia were enrolled, with 24 excluded (Supplementary Data). The remaining 445 patients included 124 with CAP and 321with HCAP, with characteristics summarized in Table 1 . Among the HCAP patients, 292 had a history of contact with the hospital in the past 30 days and 145 were residents of nursing homes or extended-care facilities. The nursing home population is compared to the other HCAP patients in Supplementary Tables 1-3 . Using the algorithm, the 321 HCAP patients were classified into groups 1 (n = 110), 2 (n = 92), 3 (n = 41), and 4 (n = 78) ( Figure 2 ). HCAP patients were significantly older than CAP patients (mean, 79.7 ± 10.4 vs 68.7 ± 15.9 years; P < .001) and had altered mental status more often. Patients with at least 1 underlying disease were more common with HCAP (100%) than with CAP (59.7%). HCAP patients had significantly more MDR risk factors than CAP patients (mean, 1.8 ± 1.3 vs Figure 1 . An algorithm for healthcare-associated pneumonia therapy based on severity of illness on admission and the presence of risk factors for multidrug-resistant pathogens. Adapted from Brito and Niederman [2] . Abbreviations: CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; ICU, intensive care unit; MDR, multidrug-resistant.
0.2 ± 0.4; P < .001; Table 1 ). ADL, evaluated with the Barthel Index, and the nutritional status (serum albumin) were significantly more impaired in HCAP than in CAP patients ( Table 2) .
Etiology of Pneumonia
A microbiologic diagnosis was established in 51.6% (64/124) of CAP patients and 66% (212/321) of HCAP patients. The diagnosis was definitive in 67.2% (43/64) and presumptive in 32.8% (21/64) of the CAP patients, and in 67.5% (142/212) and 33% (70/212) of the HCAP patients, respectively. Diagnostic procedures used to define etiology are shown in Table 3 . A mixed population of pathogens was detected in 12.9% (16/124) of CAP patients and 19.3% (62/321) of HCAP patients. Table 4 shows the frequency of the etiologic microorganisms in each patient group. Streptococcus pneumoniae was the most frequent pathogen in both HCAP and CAP patients. The frequencies of S. aureus (11.5% vs 0.8%; P < .001), MRSA (6.9% vs 0%; P = .003), Enterobacteriaceae (7.8% vs 2.4%; P = .037), P. aeruginosa (6.9% vs 0.8%; P = .01), and MDR pathogens were significantly higher in HCAP than in CAP patients (15.3% vs 0.8%; P < .001). Chlamydophila pneumoniae was equally frequent in both CAP (4.1%) and HCAP (5%) patients, whereas Mycoplasma pneumoniae was more common in CAP than in HCAP patients (8.9% vs 4.0%; P = .044; Table 4 ). Among the HCAP patients with ≥2 MDR risk factors (groups 2 and 4), compared to those with 0-1 risk factor (groups 1 and 3), the frequencies of S. aureus (17.6% vs 4.6%; P < .001), MRSA (12.9% vs 0%; P < .001), P. aeruginosa (11.2% vs 2%; P = .001), and MDR pathogens (27.1% vs 2%; P < .001) were higher (Table 5 ).
Severity and Prognosis
The 30-day mortality was higher in HCAP patients than in CAP patients (13.7% vs 5.6%; P = .017), consistent with a higher severity of illness in the HCAP patients, as reflected by higher (P < .001) values for the CURB-65 score and the PSI (Table 2) . Among HCAP patients, the 30-day mortality was significantly lower in patients with 0-1 risk factor (groups 1 and 3) compared to patients with ≥2 MDR risk factor (groups 2 and 4) (8.6% vs 18.2%; P = .012; Figure 3) . Similarly, the mean PSI score, CURB-65 score, and need for ICU admission and mechanical ventilation were significantly lower in HCAP Figure 2 . Classification of pneumonia patients in the current study using the algorithm in Brito and Niederman [2] . The specific antibiotic regimens for community-acquired and healthcare-associated pneumonia therapy are listed. Abbreviations: CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; ICU, intensive care unit; MDR, multidrug-resistant.
patients with 0-1 risk factor than in the patients with ≥2 MDR risk factors: 113.8 ± 33.4 vs 127.5 ± 31.3 (P < .001), 2.1 ± 1.1 vs 2.5 ± 1.2 (P = .002), and 27.2% vs 45.9% (P < .001), respectively.
HCAP patients with and without severe illness were compared (groups 3 and 4 vs groups 1 and 2). The 30-day mortality rate for those with severe illness was higher (30.3%) than for those without severe illness (4%; P < .001; Supplementary Table) .
Those with severe illness also had more impairment of ADL, as reflected by a significantly lower Barthel Index score (P = .006).
Therapy
Four hundred fifteen patients (93.3%) received recommended therapy. One hundred sixteen CAP patients (93.5%) received CAP therapy and 299 HCAP patients (93.1%) were treated in accordance with the algorithm [11] . The remaining 30 patients were treated with other regimens and survived, and were included in the statistical analyses. According to the algorithm, among the 321 HCAP patients, 151 could receive CAP therapy and did not need a multidrug HAP regimen (Figure 2) . A pathogen was identified in 64 CAP patients, and only 2 (3.1%) received inappropriate therapy, whereas a pathogen was identified in 212 HCAP patients, and only 15 (7.1%) received inappropriate therapy. Among low-risk HCAP patients (groups 1 and 3), the initial empiric therapy was not appropriate in 3 patients who had P. aeruginosa. In the 12 HCAP patients in groups 2 and 4 who received inappropriate therapy, the reason was usually because of MRSA not being empirically treated, or the presence of MDR P. aeruginosa or ESBL-producing gram-negative bacteria that were resistant to initial broad-spectrum therapy.
HCAP patients with 0-1 MDR risk factor received inappropriate therapy using a CAP regimen 3.2% of the time (the same as for CAP patients receiving a CAP regimen), whereas those with ≥2 MDR risk factors received inappropriate therapy using a HAP regimen 10.1% of the time. In both CAP and HCAP groups, treatment failure (in 14 CAP patients [11.3%] and 63 HCAP patients [19.3%]) was more common than inappropriate therapy.
Multivariate Mortality Analysis
The Barthel Index score, partial pressure of arterial oxygen/ fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio, dehydration (blood urea nitrogen), detection of MDR pathogens, nutritional status (albumin), PSI score, and initial treatment failure were significant predictors of 30-day mortality (dependent variable) in the univariate logistic regression analysis (Table 6 ). In the multivariate analysis, the independent predictors of 30-day mortality were the nutritional status (albumin), PSI score, and initial treatment failure. Initial treatment failure was associated with an odds ratio of mortality of 72 (Table 6 ). Appropriateness of initial empiric therapy did not emerge as a mortality risk in either the univariate or multivariate analysis, but the frequency of inappropriate therapy was low in both the HCAP and CAP populations (7.1% and 3.1%, respectively). 
DISCUSSION
In this prospective study of 445 pneumonia patients admitted to 6 Japanese hospitals, HCAP was more common than CAP (321 patients vs 124 patients) and was associated with a higher mortality rate. HCAP patients were older, presented more often with altered mental status, and had more comorbid illness, higher disease severity, more functional impairment, and more MDR pathogens than CAP patients. However, the subgroups of HCAP patients with 0-1 MDR risk factor had a low frequency of MDR pathogens, 2%, which was similar to the 0.8% rate in CAP patients, and in contrast to the 27.1% frequency in HCAP patients with ≥2 MDR risk factors. We used the presence of MDR risk factors to guide initial antibiotic therapy according to an algorithm (Figures 1 and 2) , which was followed in 299 (93.1%) of the 321 HCAP patients. With the algorithm, CAP therapy was recommended for 151 HCAP patients with 0-1 MDR risk factor, whereas broad-spectrum HAP therapy was recommended for 170 HCAP patients with ≥2 risk factors. Using this approach, only 7.1% of HCAP patients received inappropriate therapy (3.2% in those with 0-1 risk factor and 10.1% in those with ≥2 risk factors). Despite the high rate of appropriate therapy, the mortality rate for those with HCAP was higher than for those with CAP, and the mortality rate for HCAP patients with ≥2 risk factors for MDR pathogens was higher than for those at low risk (18.2% vs 8.6%; P = .012; Figure 3 ). Inappropriate therapy was not a risk for 30-day mortality by either univariate or multivariate analysis, but in the multivariate model (Table 6 ), HCAP mortality risks were malnutrition (low serum albumin), high PSI score, and initial treatment failure; only in the univariate analysis was functional impairment, defined by the Barthel Index, a risk factor. Thus, patient factors, but not antibiotic choice, were associated with HCAP mortality, likely because of the high rate of appropriate therapy that occurred by following the algorithm.
Our findings are consistent with previous studies that report a higher mortality rate in patients with HCAP than with CAP [4, 5, 8] . In previous HCAP studies, the impact of therapy choice on mortality has been variable, with a few investigators reporting reduced mortality if therapy was consistent with international guidelines [7, 22] . In contrast, one study has reported that the use of a broad-spectrum HAP regimen for patients with HCAP was a risk factor for increased mortality [23] , whereas in other studies, the majority of HCAP patients Abbreviation: BAL, bronchoalveolar lavage.
were not treated with a broad-spectrum HAP regimen, but still achieved a good outcome [6, 8, [24] [25] [26] . However, in contrast to our findings, not all of these studies included patients needing ICU admission, few patients had an established etiologic diagnosis, and most patients did not have multiple MDR risk factors. In our study, we included a large number of severely ill HCAP patients needing mechanical ventilation or ICU admission (119/321 [37%]) and identified an etiologic pathogen in 66% of HCAP patients. Recently, Micek et al reported MRSA in 26.2% of HCAP patients and P. aeruginosa in 23%, leading them to recommend targeting of these pathogens in all of their HCAP patients, a recommendation that is not supported in our patient population [27] . We did extensive diagnostic testing to obtain a microbiologic diagnosis (Tables 3 and 4) . Few epidemiological studies of HCAP have investigated atypical pathogens [28] , so we routinely performed urinary antigen tests, serological tests, real-time PCR, and culture to detect atypical pathogens, and C. pneumoniae was diagnosed based on recommendations of the Centers for Disease Control and Prevention [29] . We found that atypical pathogens were important in both HCAP and CAP, although the incidence of Legionella pneumophila pneumonia is low in Japan [30, 31] . (22), extended-spectrum β-lactamase-producing Enterobacteriaceae (7; includes E. coli [4] , K. pneumoniae [2] , and P. mirabilis [1] ), P. aeruginosa (22) , and Acinetobacter baumannii (2) in All HCAP. e Influenza virus included influenza A (3) and influenza B (3) in CAP and influenza A (9) in All HCAP.
Severity of illness was an important risk factor, which was associated with an increased mortality and more impaired functional status, as in other studies [32, 33] . The risk factors that we studied are similar to ones used by others, but we did not attempt to weight these risk factors by giving greater importance to specific findings, as was done by Shorr et al [34, 35] . However, their risk scoring system has not been used prospectively to guide antibiotic selection, as was done in our study.
In our study, initial treatment failure was the most important prognostic factor for 30-day mortality for HCAP patients. As this occurred in the setting of a high rate of appropriate therapy, and because the frequency of treatment failure (19.6%) exceeded the rate of inappropriate therapy (7.1%), it is likely that treatment failure reflected patient factors and was not a consequence of therapy choice. Similarly, the higher mortality in HCAP compared to CAP is more a reflection of differences in patient features, and not therapy choice.
It is important to treat HCAP patients with appropriate therapy, but without the overuse of antibiotics. The existing ATS/IDSA guidelines advocate broad-spectrum empiric therapy for all HCAP patients, whereas our data, and that of others, show that this is not necessary for all HCAP patients. Our findings emerged from a prospective, multicenter study, and all of Thirty-day mortality in community-acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP), with each HCAP stratified by the number of multidrug-resistant (MDR) pathogen risk factors. The 30-day mortality was significantly increased in HCAP patients with ≥2 MDR risk factors compared to HCAP patients with 0-1 MDR risk factor, which in turn was not different from the mortality of CAP patients. CAP patients and HCAP patients with 0-1 MDR risk factor were treated with CAP therapy (a β-lactam and a macrolide, or a quinolone), whereas HCAP patients with ≥2 MDR risk factors were treated with hospital-acquired pneumonia therapy (2-or 3-drug regimen: an antipseudomonal β-lactam in combination with a quinolone or aminoglycoside, plus either linezolid or vancomycin if there was concern about methicillin-resistant Staphylococcus aureus).
the centers were in Japan; therefore, the relevance to other countries needs to be determined, although the risk factors that we studied are universal. However, in our study the frequency of MRSA was 0% in CAP and 6.9% in HCAP, and countries with higher rates may need to modify the approach that is used. In addition, although our algorithm was generally effective, it still needs refinement, with consideration of other MDR risk factors, and with weighting of the relative importance of the risk factors that we did include. This might allow identification of a population with an even lower risk for MDR pathogens than our lowrisk group, which still had these organisms present in 2% of patients. In the future, large-scale randomized controlled trials of HCAP therapy using therapeutic algorithms that consider local microbiology are needed. In addition, any algorithm will also need to consider the frequency of atypical pathogens, which may be present in both HCAP and CAP patients.
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